Giving Patients Hope

Week in Review: Making Progress to Give Patients Hope

09.20.13 | By

As Senior VP of Communications Matt Bennett noted on the Catalyst this week, years of hard work go into developing and testing new medicines, and this perseverance has resulted in great progress in clinical trial research. A new person is affected by Alzheimer’s every 70 seconds, and clinical trials not only provide patients with devastating diseases like cancer and Alzheimer’s with innovative new treatments, they also provide hope for the future for patients across the country. More than 7,800 clinical trials have been piloted in Florida during the last 14 years, benefitting thousands of patients. In Arizona, clinical trials are helping researchers better understand Alzheimer’s disease, which affects 5.3 million people.  

Clinical trials strive to eliminate devastating diseases and build better lives for patients around the world. As a result, PhRMA and the European Federation of Pharmaceutical Industries and Associations (EFPIA) agreed to  the Principles for Responsible Clinical Trial Data Sharing in July  to support patient care, expand research and recognize the importance of protecting patient privacy.

Patient privacy is especially important given recent discussions around clinical trials data sharing in Europe. A new paper from Pugatch Consilium highlighted specific problems with a draft policy by the European Medicines Agency (EMA), including gaps in patient privacy protection, and a Pharmaceutical Executive blog by one of the authors suggested that the draft policy could impact pharmaceutical research in Europe.

Innovation can only move forward if the entire health care ecosystem works together to ensure we create an environment that promotes R&D. As Eli Lilly and Company CEO John Lechleiter said in a Forbes article this week, “[By] working together in partnership, progress is indeed possible.” For more on the progress we are making, check out “Conversations” where experts discuss the biopharmaceutical pipeline and what they hope to see in the near future.  


Hide Comments

More On PhRMA — powered by PhRMApedia


Cost in Context